What is NK:IO?
NK:IO is a London-based biotechnology firm focused on pioneering off-the-shelf cell therapies designed to target solid tumors. The company's innovative approach aims to streamline the development and application of cellular treatments, potentially addressing a critical need in oncology. Its strategic positioning within the UK's burgeoning life sciences sector highlights its potential for significant growth and impact.
How much funding has NK:IO raised?
NK:IO has raised a total of $1.5M across 1 funding round:
Angel/Seed
$1.5M
Angel/Seed (2023): $1.5M with participation from Cancer Research Horizons, Meltwind, and Start Codon
Key Investors in NK:IO
Cancer Research Horizons
Cancer Research Horizons is a company operating in the Research industry, based in London, UK. It likely focuses on funding and advancing novel cancer research initiatives.
Meltwind
Meltwind is an investor participating in this funding round, contributing to NK:IO's strategic growth and development in the cell therapy sector.
Start Codon
Start Codon is a UK-based life sciences accelerator and venture builder that invests in early-stage disruptive innovations, providing crucial backing and guidance for companies like NK:IO.
What's next for NK:IO?
The recent major strategic investment signals a pivotal phase for NK:IO, likely enabling the company to accelerate its research and development pipeline, scale its operational capacity, and advance its cell therapy candidates towards clinical trials. This capital infusion is expected to bolster its efforts in tackling solid tumors, positioning NK:IO for further expansion and market penetration in the competitive biotech landscape.
See full NK:IO company page
